Skip to Main Content

Paper Details

Financially effective test algorithm to identify an aggressive, EGFR-amplified variant of IDH-wildtype, lower-grade diffuse glioma.
Neuro Oncol
22
2019
CNS Tumor, Cancer, EGFR, EGFR-amplified tumors, IDH, IDH-wildtype, WHO grade II/III gliomas, diffuse, diffuse gliomas, epidermal growth factor receptor, glioblastoma, glioblastomas, isocitrate, isocitrate dehydrogenase, lower-grade diffuse glioma, lower-grade gliomas, tumors
Author NameAffiliation
Otto Rapalino
Maria Martinez-LageMassachusetts General Hospital
Maria Martinez-LageMassachusetts General Hospital
Matthew P FroschMassachusetts General Hospital
Matthew P FroschMassachusetts General Hospital
Tracy T BatchelorMassachusetts General Hospital
Tracy T Batchelor
Tracy T Batchelor
Tracy T BatchelorMassachusetts General Hospital
Tracy T Batchelor
Tracy T Batchelor
David N LouisMassachusetts General Hospital
Anthony J IafrateMassachusetts General Hospital
Jochen K LennerzMassachusetts General Hospital
  • 1 - 14

Datasets

Release 1.2